Used in targeted cancer therapies, particularly for small cell lung cancer (SCLC) and other neuroendocrine tumors. Binds specifically to DLL3 (Delta-like ligand 3), a protein highly expressed on tumor cells but limited in healthy tissues, enabling precise targeting. Employed as a reference in the development of antibody-drug conjugates (ADCs) and bispecific antibodies to evaluate binding affinity, specificity, and efficacy. Supports research in tumor imaging and diagnostic applications. Also utilized in preclinical studies to benchmark therapeutic antibodies and optimize drug candidates in oncology pipelines.